The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.

The triggering receptor expressed on myeloid cells 2 (TREM2) plays a pivotal role in the activation of myeloid cells and is currently being investigated as a potential therapeutic target in several ...

Using brain gene expression maps from the Allen Human Brain Atlas, the researchers tested the degree to which Alzheimer’s risk genes explain the patterns of both actual and residual tau. This allowed ...

It's been recognized for some time that Alzheimer's disease affects brain regions differently and that tau—a protein known to ...

These include amyloid PET, approved cerebrospinal fluid (CSF) biomarkers, and certain plasma biomarkers like phosphorylated tau 217 (p-tau217) that map into either the amyloid-beta (Aβ) or ...

Alzheimer disease (AD) and diverse non-AD tau pathologies may contribute to late-life mood disorders (LLMDs), according to a study.

Education -- a proxy for cognitive reserve -- often correlates with better cognition, greater gray matter volume, improved ...